NCT02815033View on ClinicalTrials.gov

Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

June 30, 2020

Study Completion Date

December 31, 2020

Conditions
Prostate Cancer Metastatic
Interventions
DRUG

Enzalutamide

PROCEDURE

11C or 18F-Choline PET/CT

PROCEDURE

Whole body MRI

PROCEDURE

Bone scan

Trial Locations (1)

2333 ZA

Leiden University Medical Center, Leiden

All Listed Sponsors
collaborator

Centre for Human Drug Research, Netherlands

OTHER

lead

The European Uro-Oncology Group

OTHER

NCT02815033 - Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide | Biotech Hunter | Biotech Hunter